Neurocarrus

Neurocarrus is developing a breakthrough therapeutic biologic (N-001) for severe pain that is non-addictive, long-lasting, and specific

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lincoln, NE, USA
  • Currency USD
  • Founded December 2017
  • Employees 4
  • Incorporation Type C-corp
  • Website neurocarrus.com

Company Summary

Neurocarrus is a biotech company developing a novel, non-opioid therapeutic for chronic pain. Our first-in class drug delivery technology can safely disrupt pain signals without addiction-forming medications or disruption of muscular control, while avoiding the side effects of systemically absorbed drugs.

Neurocarrus seeks investment to advance drug testing through pre-clinical testing to human trials. State matching funds are available.

Team

  • Paul Blum, PhD
    CEO and Co-founder

    Paul brings over 25 years of research experience and insight in protein engineering and microbiology with an emphasis on multidomain proteins and enzymes.
    Paul earned his Ph.D from the University of California, Davis, and a B.S. from the University of California, Berkeley. He completed his postdoctoral fellowships at UC Berkeley and Stanford Medical School.

  • Neurocarrus Inc
    Research Scientist

    Derek's role in the company involves the production of the lead compound N-001 and the testing of safety and efficacy in animal and cell culture models. His previously published papers found the initial mechanism of action of the drug along with the early efficacy and safety data in animals.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free